Interestingly, initial therapeutic outcomes of 225Ac-PSMA-617 TAT from both the studies are encouraging, and if proved to be consistent in the future studies, this radiopharmaceutical may have an essential place in the field of prostate cancer management. The gene discussed is FOLH1; the disease is prostate carcinoma.